JPS6015616B2 - Method for producing N-2-(pyrrolidinylmethyl)-substituted benzamide derivative or salts thereof - Google Patents

Method for producing N-2-(pyrrolidinylmethyl)-substituted benzamide derivative or salts thereof

Info

Publication number
JPS6015616B2
JPS6015616B2 JP50027573A JP2757375A JPS6015616B2 JP S6015616 B2 JPS6015616 B2 JP S6015616B2 JP 50027573 A JP50027573 A JP 50027573A JP 2757375 A JP2757375 A JP 2757375A JP S6015616 B2 JPS6015616 B2 JP S6015616B2
Authority
JP
Japan
Prior art keywords
pyrrolidinylmethyl
group
formula
hydrogen atom
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP50027573A
Other languages
Japanese (ja)
Other versions
JPS50123668A (en
Inventor
ビユルト− ジエラ−ル
アシエ ジヤツク
クロ−ド モニエ ジヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DECHUUDO SHIANTEIFUIIKU E IND DO RIRU DO FURANSU SOC
Original Assignee
DECHUUDO SHIANTEIFUIIKU E IND DO RIRU DO FURANSU SOC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7407535A external-priority patent/FR2262966A1/en
Priority claimed from FR7503800A external-priority patent/FR2299863B1/en
Application filed by DECHUUDO SHIANTEIFUIIKU E IND DO RIRU DO FURANSU SOC filed Critical DECHUUDO SHIANTEIFUIIKU E IND DO RIRU DO FURANSU SOC
Publication of JPS50123668A publication Critical patent/JPS50123668A/ja
Publication of JPS6015616B2 publication Critical patent/JPS6015616B2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/282-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Description

【発明の詳細な説明】 本発明は新規なN−(2ーピロリジニルメチル)置換ペ
ンズアミド議導体およびその薬学的に許容され得る酸附
加塩または第4級アンモニウム塩類の製造法に関するも
のである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel N-(2-pyrrolidinylmethyl)-substituted penzamide derivative and a method for producing its pharmaceutically acceptable acid salts or quaternary ammonium salts. .

本発明の目的物質ペンズアミド譲導体は、次の一般式で
示される。
The target penzamide derivative of the present invention is represented by the following general formula.

〔式中、Aは水素原子または低級アルキル基×は水素原
子または低級アルコキシ基、Yは水素原子またはアミノ
基、Zは水素藤子、ハロゲン原子、低級ァルコキシ基、
低級アルキルスルホニル基またはS02NR,R2基(
ここでR,およびR2は同一または異なっていて、水素
または低級アルキル基である。
[In the formula, A is a hydrogen atom or a lower alkyl group x is a hydrogen atom or a lower alkoxy group, Y is a hydrogen atom or an amino group, Z is hydrogen Fujiko, a halogen atom, a lower alkoxy group,
Lower alkylsulfonyl group or S02NR, R2 group (
Here, R and R2 are the same or different and are hydrogen or a lower alkyl group.

)をそれぞれ意味する〕本発明による反応は下記のとお
りである。一般式〔式中、Bはハロゲン原子またはヒド
ロキシ基、A、X、YおよびZは前記と同じ〕で表わさ
れる化合物またはその反応性誘導体に、で表わされる右
旋性、左旋性またはラセミ型のアミンまたはその反応性
誘導体を反応せしめることにより前記目的物質N一(2
−ピロリジニルメチル)置換ペンズァミド誘導体(1)
を得、必要に応じて、その薬学的に許容され得る酸附加
塩または第4級アンモニウム塩類に導く。
) respectively]] The reaction according to the present invention is as follows. A compound represented by the general formula [wherein B is a halogen atom or a hydroxy group, and A, By reacting an amine or a reactive derivative thereof, the target substance N1 (2
-pyrrolidinylmethyl) substituted penzamide derivative (1)
and, if necessary, convert it into pharmaceutically acceptable acid salts or quaternary ammonium salts thereof.

上記化合物(1)および(ロ)中のA、XおよびZの定
義において、低級アルキルおよび低級アルコキシの例と
しては、C,‐5のアルキルおよびC,−5のアルコキ
シが挙げられる化合物(ロ)の反応性誘導体はカルボキ
シ基における反応性議導体であって、例えば、メチルヱ
ステル、エチルエステル、プロピルエステル、ブチルエ
ステル、イソブチルエステル、ベンチルヱステル等のカ
ルボン酸ェステル類、シアノメチルエステル、メトキシ
メチルエステル、Nーヒドロキシイミドェステルの如き
反応性ェステル類、置換または非贋換芳香族ヱステル類
、酸ヒドラシド、酸ァジド、対称型酸無水物、ハロ蟻酸
低級アルキルの如き混合酸無水物、トリアゾリド、テト
ラゾリドまたはイミダゾリドの如きアゾリドおよびィソ
シアネート等を例示し得るが、本発明はこれらの誘導体
に限定されない。
In the definitions of A, X and Z in the above compounds (1) and (b), examples of lower alkyl and lower alkoxy include C, -5 alkyl and C, -5 alkoxy. The reactive derivatives of are reactive derivatives at the carboxy group, such as carboxylic acid esters such as methyl ester, ethyl ester, propyl ester, butyl ester, isobutyl ester, benzyl ester, cyanomethyl ester, methoxymethyl ester, N- reactive esters such as hydroxyimide esters, substituted or unsubstituted aromatic esters, acid hydracides, acid azides, symmetrical acid anhydrides, mixed acid anhydrides such as lower alkyl haloformates, triazolides, tetrazolides or imidazolides; Examples include azolides and isocyanates, but the present invention is not limited to these derivatives.

本発明において、アミン(m)の反応性誘導体としては
、アミンの燐塩化物、オキシ塩化燐、ジアルキルまたは
ジアリールあるいはオルトフエニレンクロロホスフアイ
ト、アルキルまたはアリールジクロ。
In the present invention, reactive derivatives of the amine (m) include phosphorus chlorides, phosphorus oxychlorides, dialkyl or diaryl or orthophenylenechlorophosphites, alkyl or aryl dichlorides of the amine.

ホスフアィトとの反応生成物、あるいはアミンのイソチ
オシアネート等を使用することができる。これらの反応
性誘導体はそのま)または分離した後、酸と反応させる
。また、遊離酸と遊離アミンを四塩化碇素、無水燐酸ま
たはジシクロヘキシルカルボジィミドの如きカルボジィ
ミド等の縮合剤の存在下で反応させることも可能である
A reaction product with a phosphite or an isothiocyanate of an amine can be used. These reactive derivatives can be reacted as such or after separation with an acid. It is also possible to react the free acid and the free amine in the presence of a condensing agent such as silicate tetrachloride, phosphoric anhydride or a carbodimide such as dicyclohexylcarbodimide.

本発明のアミド化反応は溶媒の存在下または不存在下で
行われる。アミド化反応に不活性の使用し得る溶媒とし
ては、例えばアルコール類、ボリオール類、ベンゼン、
トルェン、ジオキサン、クロロホルム、ジエチレングリ
コールジメチルエーテル等を挙げることができる。また
、出発物質として使用するアミンの過剰量を溶媒を兼ね
て使用することもできる。アミド化反応は、例えば上記
溶媒の沸点に加熱して行うのが好ましい。本発明の方法
によって得られる化合物は、必要に応じて、塩酸、ブロ
ム水素酸、硫酸、燐酸、酢酸、酒石酸、クエン酸、メタ
ンスルホン酸等の薬学的に許容され得る無機酸または有
機酸との酸附加塩に導くことができまた必要に応じてア
ルキル硫酸、またはアルキルハラィド等と反応させて第
4級アンモニウム塩に導くこともできる。
The amidation reaction of the present invention is carried out in the presence or absence of a solvent. Examples of inert solvents that can be used in the amidation reaction include alcohols, polyols, benzene,
Examples include toluene, dioxane, chloroform, diethylene glycol dimethyl ether, and the like. Moreover, an excess amount of the amine used as a starting material can also be used as a solvent. The amidation reaction is preferably carried out by heating to the boiling point of the solvent, for example. The compounds obtained by the method of the present invention may be combined with pharmaceutically acceptable inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, tartaric acid, citric acid, methanesulfonic acid, etc., if necessary. It can be converted into a salt with an acid, and can also be converted into a quaternary ammonium salt by reacting with an alkyl sulfuric acid, an alkyl halide, etc., if necessary.

本発明によって得られるペンズアミドは顕著な治療活性
を有し、殊に制吐剤、抗潰傷剤、中枢神経系改善剤とし
て有用である。その毒性は低く、副作用を示す危険性な
く人間の治療に用いることができる。本発明の技術的特
徴を示すために、以下実施例を示すが、本発明はこれら
に限定されるものではない。
The penzamides obtained according to the invention have significant therapeutic activity and are particularly useful as antiemetics, antiulcer agents and central nervous system improving agents. Its toxicity is low and it can be used for human treatment without the risk of exhibiting side effects. Examples are shown below to demonstrate the technical features of the present invention, but the present invention is not limited thereto.

実施例 1 N−(Zーピロリジニルメチル)一2ーメトキシー4ー
アミノ−5−クロロベンズアミド塩酸塩2ーメトキシ−
4ーアセトアミドー5ークロロ安息香酸メチル51.5
夕、水20の【および2ーアミ/メチルピロリジン40
夕を鷹梓器および温度計を備えた丸底フラスコに導入す
る。
Example 1 N-(Z-pyrrolidinylmethyl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride 2-methoxy-
Methyl 4-acetamido-5-chlorobenzoate 51.5
Evening, water 20 [and 2-amino/methylpyrrolidine 40
The mixture is introduced into a round bottom flask equipped with a thermometer and thermometer.

この混合物を7時間加熱還流させた後、冷却する。これ
に水50の【および40%水酸化ナトリウム溶液50の
‘を加えて2時間加熱還流する。冷却後生成する結晶を
水洗し、乾燥器中50qoで乾燥すると、目的のペンズ
アミド32夕が遊離塩として得られる。この塩基の熱ア
ルコール溶液を熱時炉過し、塩酸(d=1.18)を加
えると塩酸塩が析出する。
The mixture is heated to reflux for 7 hours and then cooled. To this was added 50 parts of water and 50 parts of 40% sodium hydroxide solution, and the mixture was heated under reflux for 2 hours. After cooling, the resulting crystals are washed with water and dried at 50 quarts in a dryer to obtain the desired penzamide 32 as a free salt. This hot alcoholic solution of the base is filtered in a hot oven and hydrochloric acid (d=1.18) is added to precipitate the hydrochloride.

冷後、生成した結晶を炉取し、エタノールで洗渡し、乾
燥器中50qoで乾燥すると、N一(2ーピロリジニル
メチル)一2ーメトキシー4ーアミノー5ークロロベン
ズアミド塩酸塩24.2夕が得られる(融点:1670
)。実施例 2 N一(2′ーピロリジニルメチル)一2ーメトキシー4
−アミノ−5ースルフアモイルベンズアミド2−メトキ
シー4−アミノ−5ースルフアモイル安息香酸メチル1
40夕、水48.5の‘および2−アミノメチルピロリ
ジン80夕を冷却器を備えた1そのフラスコに導入する
After cooling, the formed crystals were taken in a furnace, washed with ethanol, and dried at 50 qo in a dryer to give N-(2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-chlorobenzamide hydrochloride at 24.2 qq. obtained (melting point: 1670
). Example 2 N-(2'-pyrrolidinylmethyl)-2-methoxy4
-Amino-5-sulfamoylbenzamide 2-methoxy-4-amino-5-sulfamoylbenzoate methyl 1
After 40 minutes, 48.5 parts of water and 80 parts of 2-aminomethylpyrrolidine are introduced into a flask equipped with a condenser.

得られる懸濁液を水浴上で加熱する。冷却後、反応混合
物を水540叫で希釈し、生ずる固体を炉取し、水洗し
、460で乾燥する。生成した塩基を塩酸塩に導き、2
0%アンモニア水で再沈澱させ、炉取し、洗総して50
℃で乾燥すると、N一(2−ピロリジニルメチル)−2
ーメトキシー4ーアミノー5ースルフアモイルベンズア
ミド97夕が得られる(収率:54.8%、融点205
〜206℃)。
The resulting suspension is heated on a water bath. After cooling, the reaction mixture is diluted with 540 °C of water and the resulting solid is taken off, washed with water and dried at 460 °C. The generated base is converted into hydrochloride, and 2
Re-precipitate with 0% ammonia water, take out the furnace, wash thoroughly and
When dried at ℃, N-(2-pyrrolidinylmethyl)-2
-Methoxy4-amino-5-sulfamoylbenzamide 97% is obtained (yield: 54.8%, melting point 205
~206°C).

実施例 3 N一(2ーピロリジニルメチル)一2−メトキシー5−
エチルスルホニルベンズアミドN−ペンジルー2−アミ
ノメチルピロリジン130夕、メチルエチルケトン62
0の【および温度を5〜1ぴ0に維持しながら2ーメト
キシー5ーェチルスルホニルベンゾイルクロライド16
2.6夕を、縄梓器、冷却器および温度計を備えた2そ
のフラスコに導入する。
Example 3 N-(2-pyrrolidinylmethyl)-2-methoxy5-
Ethylsulfonylbenzamide N-penzyl-2-aminomethylpyrrolidine 130%, methyl ethyl ketone 62
0 and 2-methoxy-5-ethylsulfonylbenzoyl chloride 16 while maintaining the temperature between 5 and 10.
2.6 hours is introduced into a flask equipped with a strainer, condenser and thermometer.

これを加熱せずに1時間蝿拝する。生成する結晶を炉過
し少量のメチルエチルケトンで洗総し、熱エタノールに
熔解する。冷却後生成する結晶を炉取し、洗総し、乾燥
し、つぎにこれを水500の‘、ラネーニツケル150
夕と共に1そのオートオートクレープに入れ、圧力17
0k9になるまで水素を導入する。混合物を10ぴ0に
4時間加熱する。冷却後ニッケルを炉取し水で洗液する
。溶媒を減圧で溜去し、残澄を36%塩酸25机‘と水
の混液で液量が500泌になるまで処理する。80℃に
加熱した後炉過し、40%水酸化ナトリウム溶液でアル
カリ性にする。
Let this sit for an hour without heating. The resulting crystals are filtered, washed with a small amount of methyl ethyl ketone, and then dissolved in hot ethanol. After cooling, the crystals formed are taken out in a furnace, washed and dried, and then mixed with 500 g of water and 150 g of Raney nickel.
Put it in the autoclave with the mixture and reduce the pressure to 17.
Hydrogen is introduced until the temperature reaches 0k9. Heat the mixture to 10°C for 4 hours. After cooling, the nickel is washed with water taken from the furnace. The solvent was distilled off under reduced pressure, and the residue was treated with a mixture of 25% 36% hydrochloric acid and water until the liquid volume reached 500%. After heating to 80°C, it is filtered and made alkaline with 40% sodium hydroxide solution.

冷却後生成した結晶を炉取し、水洗し、乾燥すると、N
−(2′ーピロリジニルメチル)一2−メトキシ−5ー
エチルスルホニルベンズアミド111.5夕が得られる
(収率:70.3%、融点:150q○)。実施例 4 N一(2ーピロリジニルメチル)−2ーメトキシー4ー
アミノベンズアミド2ーアミノメチルピロリジン2夕の
ピリジン溶液中に、三塩化燐1.4夕をピリジン8の‘
に溶解した溶液を温度を0〜5℃に保持しながら蝿洋下
に滴下する。
After cooling, the crystals formed are taken out in a furnace, washed with water, and dried.
111.5 ml of -(2'-pyrrolidinylmethyl)-2-methoxy-5-ethylsulfonylbenzamide is obtained (yield: 70.3%, melting point: 150q○). Example 4 N-(2-pyrrolidinylmethyl)-2-methoxy-4-aminobenzamide 2-aminomethylpyrrolidine In a solution of 2 parts of pyridine, 1.4 parts of phosphorus trichloride was added to 8 parts of pyridine.
The solution dissolved in the solution is dropped into the fly bath while maintaining the temperature at 0 to 5°C.

更に0〜5℃、ついで常温で損梓を続ける。これに2ー
メトキシー4ーアミノ安息香酸1.6夕を加えた後、混
合物を数時間加熱蝿拝する。反応混合物を冷却し、溶媒
を除去した後、残溝をクロロホルムに溶解し、この溶液
を炭酸ナトリウム水溶液で洗糠し、無水硫酸マグネシウ
ムで乾燥する。
Further heating is continued at 0 to 5°C and then at room temperature. After adding 1.6 g of 2-methoxy-4-aminobenzoic acid to this, the mixture was heated for several hours. After the reaction mixture is cooled and the solvent is removed, the residue is dissolved in chloroform, this solution is washed with an aqueous sodium carbonate solution, and dried over anhydrous magnesium sulfate.

減圧で濃縮すると、N−(2′ーピロリジニルメチル)
−2ーメトキシー4ーアミノーペンズアミド1.5夕が
得られる(収率:62.8%、融点:98℃)。実施例
5 N一(2ーピロリジニルメチル)−2ーメトキシ−5ー
メチルスルホニルベンズアミド欄枠器および温度計を備
えた丸底フラスコ中に、メチルエチルケトン750の【
、Nーベンジルー2ーアミノメチルピロリジン103夕
を入れ、つぎに温度を15〜20午0に維持しながら2
ーメトキシー5ーメチルスルホニルベンゾイルクロライ
ド133夕を導入する。
Concentration under reduced pressure yields N-(2'-pyrrolidinylmethyl)
1.5 times of -2-methoxy 4-aminopenzamide is obtained (yield: 62.8%, melting point: 98°C). Example 5 N-(2-pyrrolidinylmethyl)-2-methoxy-5-methylsulfonylbenzamide In a round bottom flask equipped with a column vessel and a thermometer, methyl ethyl ketone 750
, N-benzyl-2-aminomethylpyrrolidine 103 ml was added, and then 2 ml was added while maintaining the temperature at 15-20 pm.
-Methoxy-5-methylsulfonylbenzoyl chloride 133 is introduced.

反応混合物を常温で2時間燈拝を続ける。生成した固体
を炉過し、氷冷したメチルエチルケトンで処理してエタ
ノールに溶解する。冷却して得られる結晶を炉過し、洗
総し、乾燥し、つぎにこれを5そのオートクレープ中に
水1夕およびラネーニッケル20夕と共に導入する。密
閉後、130k9の圧力で水素を導入し、混合物を10
0℃に4時間加熱する。冷却後、ニッケルを炉過し洗篠
する。
The reaction mixture was allowed to stand at room temperature for 2 hours. The resulting solid is filtered, treated with ice-cold methyl ethyl ketone, and dissolved in ethanol. The crystals obtained on cooling are filtered, rinsed and dried, and then introduced into an autoclave with 1 night of water and 20 nights of Raney nickel. After sealing, hydrogen was introduced at a pressure of 130 k9 and the mixture was heated to 10
Heat to 0°C for 4 hours. After cooling, the nickel is filtered through a furnace and washed.

つぎに溶媒を減圧下に溜去する。残澄を水で処理し、塩
酸を加えて500叫とする。得られる溶液を80℃に加
熱し、炉遇し、水酸化ナトリウムでアルカリ性にする。
冷却後、生成する結晶を炉過し、水洗し、乾燥する。N
−(2′−ピロリジニルメチル)‐2−メトキシ−5ー
メチルスルホニル・ベンズアミド聡夕が得られる(収率
:聡.9%、融点:152.50〇)。実施例 6 N一(2′ーピロリジニルメチル)−2−メトキシ−5
ーエチルスルホニルベンズアミド2ーメトキシ−5−エ
チルスルホニル安息香酸7.3夕、テトラヒドロフラン
200のZおよびカルポニルジィミダゾール7.3夕を
灘洋器および冷却器を備えた丸底フラスコに導入する。
Next, the solvent is distilled off under reduced pressure. Treat the residue with water and add hydrochloric acid to make 500 ml. The resulting solution is heated to 80° C., heated and made alkaline with sodium hydroxide.
After cooling, the crystals formed are filtered, washed with water, and dried. N
-(2'-pyrrolidinylmethyl)-2-methoxy-5-methylsulfonyl benzamide was obtained (yield: .9%, melting point: 152.500). Example 6 N-(2'-pyrrolidinylmethyl)-2-methoxy-5
-Ethylsulfonylbenzamide 7.3 hours of 2-methoxy-5-ethylsulfonylbenzoic acid, 200 hours of Z of tetrahydrofuran, and 7.3 hours of carponyldimidazole are introduced into a round bottom flask equipped with a steamer and a condenser.

混合物を常温で3雌ご間損拝した後、2−ァミノメチル
ピロリジン4.8夕を添加する。
After the mixture was incubated at room temperature for 3 females, 4.8 hours of 2-aminomethylpyrrolidine was added.

常温で灘梓を継続した後、溶媒を減圧で溜去する。残笹
を塩酸に溶解し、得られる溶液を炉過し、水酸化ナトリ
ウムを加えて軸12−13とする。この混合液をクロロ
ホルムで抽出する。乾燥し、炉過し、溶媒を減圧で溜去
する。エタノールで精製するとN−(2′−ピロリジニ
ルメチル)一2ーメトキシー5ーェチルスルホニルベン
ズアミド6.5夕が得られ0る(収率:665%、融点
:150℃)。実施例 7N−(2−ピロリジニルメチ
ル)−2・3−ジメトキシー5ースルフアモィルベンズ
アミド塩酸塩夕 アセトン1そおよびNーベンジル−2
−アミノメチルピロリジン200夕を蝿梓器および温度
計を備えた4そのフラスコに導入する。
After continuing Nada-azusa at room temperature, the solvent was distilled off under reduced pressure. The residual bamboo is dissolved in hydrochloric acid, the resulting solution is filtered, and sodium hydroxide is added to form the shaft 12-13. This mixture is extracted with chloroform. Dry, filter and remove the solvent under reduced pressure. Purification with ethanol yields 6.5% of N-(2'-pyrrolidinylmethyl)-12-methoxy-5-ethylsulfonylbenzamide (yield: 665%, melting point: 150°C). Example 7 N-(2-pyrrolidinylmethyl)-2,3-dimethoxy-5-sulfamoylbenzamide hydrochloride Acetone 1 and N-benzyl-2
200 mg of aminomethylpyrrolidine are introduced into 4 flasks equipped with a flask and a thermometer.

この混合物を0℃に冷却し、2・3−ジメトキシ−5−
スルフアモィルベンゾィルクロラィド280夕を添加し
、反応系の温度を10℃以下に保持する。この混合物を
4時間凝辞し、生じた沈澱を炉取し、炉過器上でァセト
ンで洗練し、これを、水1200の‘、塩酸(d=1.
18)40の【およびラネーニツケル5匙と共にオート
クレープ中に導入する。
The mixture was cooled to 0°C and 2,3-dimethoxy-5-
280 mg of sulfamoylbenzoyl chloride is added and the temperature of the reaction system is maintained below 10°C. The mixture was allowed to coagulate for 4 hours, the resulting precipitate was filtered off, purified on a furnace with acetone, and mixed with 1200 parts of water, hydrochloric acid (d=1.
18) Introduce into an autoclave with 40 ml and 5 tsp.

密閉後、水素を導入して140k9の圧力にする。混合
物を100℃でで4時間加熱する。冷却後ニッケルを炉
過し、反応液をアンモニア150叫を加えてアルカリ性
にする。生ずる沈毅を炉取し、乾燥し、150の‘の無
水エタノール中に沸騰温度で溶解し、エタノール塩酸4
0の【で酸性にする。冷却後、得られる結晶を炉取し、
洗総し、50℃で乾燥する。N一(2ーピロリジニルメ
チル)一2・3−ジメトキシー5ースルフアモィルベン
ズアミド塩酸塩95夕が得られる(融点:195−1擬
℃)。実施例 8N−(2−ビロリジニルメチル)一2
−メトキシー5ースルフアモイルベンズアミド2−メト
キシー5−スルフアモィル安息香酸エチル51.8夕、
2−アミノメチルピロリジン24夕およびブタノール2
00の‘を1そのフラスコに導入する。
After sealing, hydrogen is introduced to bring the pressure to 140k9. The mixture is heated at 100° C. for 4 hours. After cooling, the nickel is filtered through a furnace, and 150 ml of ammonia is added to the reaction solution to make it alkaline. The resulting precipitate was taken off in an oven, dried, dissolved in 150' of absolute ethanol at boiling temperature, and diluted with 4 ml of ethanolic hydrochloric acid.
Make it acidic with [0]. After cooling, the obtained crystals are collected in a furnace,
Wash thoroughly and dry at 50°C. 95% of N-(2-pyrrolidinylmethyl)-2,3-dimethoxy-5-sulfamoylbenzamide hydrochloride is obtained (melting point: 195-1 pseudo°C). Example 8N-(2-pyrrolidinylmethyl)-2
-Methoxy5-sulfamoylbenzamide ethyl 2-methoxy5-sulfamoylbenzoate 51.8 minutes,
2-aminomethylpyrrolidine and butanol
00' is introduced into the flask.

混合物を7時間加熱還流する。冷却後、溶媒を減圧で溜
去した後、残澄をジメチルホルムアミドから再結晶する
と目的のペンズアミド51夕が得られる(収率:73%
)。更に再結晶を繰返すと、N−(2′−ピロリジニル
メチル)一2ーメトキシー5−スルフアモイルペンズア
ミド43夕が得られる(収率:61.5%、融点185
午C)。
The mixture is heated to reflux for 7 hours. After cooling, the solvent was distilled off under reduced pressure, and the residue was recrystallized from dimethylformamide to obtain the desired penzamide 51 (yield: 73%).
). By further repeating the recrystallization, N-(2'-pyrrolidinylmethyl)-12-methoxy-5-sulfamoylpenzamide 43 was obtained (yield: 61.5%, melting point: 185
afternoon C).

Claims (1)

【特許請求の範囲】 1 一般式 ▲数式、化学式、表等があります▼ 〔式中、Aは水素原子または低級アルキル基、Bはハロ
ゲン原子またはヒドロキシ基、Xは水素原子または低級
アルコキシ基、Yは水素原子またはアミノ基、Zは水素
原子、ハロゲン原子、低級アルコキシ基、低級アルキル
スルホニル基またはSO_2NR_1R_2基(ここで
R_1およびR_2は同一または異なつていて、水素ま
たは低級アルキル基である。 )をそれぞれ意味する〕で表わされる化合物またはその
反応性誘導体に、▲数式、化学式、表等があります▼で
表わされる右旋性、左旋性またはラセミ型のアミンまた
はその反応性誘導体を反応せしめ、 一般式▲数式、化
学式、表等があります▼ 〔式中、A、X、YおよびZは前記と同じ〕で表わされ
るN−(2−ピロリジニルメチル)置換ベンズアミド誘
導体を得、必要に応じて、その薬学的に許容され得る酸
附加塩または第4級アンモニウム塩類に導くことを特徴
とするN−(2−ピロリジニルメチル)置換ベンズアミ
ド誘導体またはその塩類の製造法。
[Claims] 1 General formula▲ Numerical formula, chemical formula, table, etc.▼ [In the formula, A is a hydrogen atom or a lower alkyl group, B is a halogen atom or a hydroxy group, X is a hydrogen atom or a lower alkoxy group, Y is a hydrogen atom or an amino group, Z is a hydrogen atom, a halogen atom, a lower alkoxy group, a lower alkylsulfonyl group, or an SO_2NR_1R_2 group (where R_1 and R_2 are the same or different and are hydrogen or a lower alkyl group). ▲There are mathematical formulas, chemical formulas, tables, etc.▼ A dextro-, levorotatory-, or racemic-type amine or its reactive derivative represented by ▼ is reacted with a compound represented by [respectively meaning] or its reactive derivative, and the general formula is ▲There are mathematical formulas, chemical formulas, tables, etc.▼ Obtain the N-(2-pyrrolidinylmethyl) substituted benzamide derivative represented by [In the formula, A, X, Y and Z are the same as above], and if necessary, 1. A method for producing an N-(2-pyrrolidinylmethyl)-substituted benzamide derivative or a salt thereof, which is characterized by leading to a pharmaceutically acceptable acid addition salt or quaternary ammonium salt thereof.
JP50027573A 1974-03-05 1975-03-05 Method for producing N-2-(pyrrolidinylmethyl)-substituted benzamide derivative or salts thereof Expired JPS6015616B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR7407535 1974-03-05
FR7407535A FR2262966A1 (en) 1974-03-05 1974-03-05 N-(2-azacycloalkyl-alkyl)-benzamide derivs. - with antiemetic, antiulcer and CNS activity
FR7503800 1975-02-07
FR7503800A FR2299863B1 (en) 1975-02-07 1975-02-07 Novel substituted N- (Z-pyrrolidiny alkyl) benzamides, their derivatives and process for their preparation

Publications (2)

Publication Number Publication Date
JPS50123668A JPS50123668A (en) 1975-09-29
JPS6015616B2 true JPS6015616B2 (en) 1985-04-20

Family

ID=26218210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50027573A Expired JPS6015616B2 (en) 1974-03-05 1975-03-05 Method for producing N-2-(pyrrolidinylmethyl)-substituted benzamide derivative or salts thereof

Country Status (27)

Country Link
JP (1) JPS6015616B2 (en)
AR (1) AR206621A1 (en)
AT (1) AT358570B (en)
BG (1) BG24666A3 (en)
CA (1) CA1047504A (en)
CH (1) CH605794A5 (en)
CS (1) CS189692B2 (en)
DD (1) DD119420A5 (en)
DE (1) DE2507989A1 (en)
DK (1) DK145377C (en)
EG (1) EG12577A (en)
ES (1) ES435274A1 (en)
FI (1) FI750620A (en)
GB (1) GB1466822A (en)
HK (1) HK14078A (en)
HU (1) HU170637B (en)
IE (1) IE40818B1 (en)
IL (1) IL46696A (en)
LU (1) LU71949A1 (en)
NL (1) NL7502608A (en)
NO (1) NO750713L (en)
OA (1) OA04966A (en)
PH (1) PH14197A (en)
PL (1) PL97091B1 (en)
RO (2) RO70647A (en)
SE (1) SE411754B (en)
SU (1) SU609464A3 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ186175A (en) * 1977-01-27 1980-03-05 Shionogi & Co Meta-sulphonamidobenzamide derivatives
SE8503054D0 (en) * 1985-06-19 1985-06-19 Astra Laekemedel Ab CATECHOLCARBOXAMIDES
US4772459A (en) * 1986-09-09 1988-09-20 Erbamont, Inc. Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
EP0314483A1 (en) * 1987-10-29 1989-05-03 Erbamont, Inc. Preparation of benzamides
FR2699533A1 (en) * 1992-12-21 1994-06-24 Mouhtaram Mohamed N-2-piperazinyl 4-amino:benzamide derivs. having antiemetic and antipsychotic activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3078497A (en) * 1960-12-29 1963-02-26 Leeds And Mieallef Dispensing containers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3078497A (en) * 1960-12-29 1963-02-26 Leeds And Mieallef Dispensing containers

Also Published As

Publication number Publication date
BG24666A3 (en) 1978-04-12
DK145377B (en) 1982-11-08
JPS50123668A (en) 1975-09-29
CA1047504A (en) 1979-01-30
NO750713L (en) 1975-09-08
IE40818L (en) 1975-09-05
DK145377C (en) 1983-04-11
AT358570B (en) 1980-09-25
HK14078A (en) 1978-03-23
LU71949A1 (en) 1976-02-04
ATA160775A (en) 1980-02-15
SE411754B (en) 1980-02-04
FI750620A (en) 1975-09-06
AR206621A1 (en) 1976-08-06
AU7874075A (en) 1976-09-09
RO72844A (en) 1981-09-24
DK86975A (en) 1975-11-03
ES435274A1 (en) 1976-12-16
SU609464A3 (en) 1978-05-30
DE2507989A1 (en) 1975-09-11
PH14197A (en) 1981-03-26
SE7502342L (en) 1975-09-06
CH605794A5 (en) 1978-10-13
CS189692B2 (en) 1979-04-30
PL97091B1 (en) 1978-02-28
IL46696A (en) 1978-07-31
DD119420A5 (en) 1976-04-20
HU170637B (en) 1977-07-28
SU609464A1 (en) 1978-05-30
RO70647A (en) 1980-04-15
OA04966A (en) 1980-10-31
EG12577A (en) 1979-09-30
GB1466822A (en) 1977-03-09
NL7502608A (en) 1975-09-09
IL46696A0 (en) 1975-04-25
IE40818B1 (en) 1979-08-29

Similar Documents

Publication Publication Date Title
JP4853965B2 (en) Adamantane derivatives and azabicyclooctane derivatives and azabicyclononane derivatives and methods for their preparation and their use as DPP-IV inhibitors
AU2005293881B2 (en) Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
JPS6058750B2 (en) Method for producing N-(1-benzylpyrrolidinyl-2-methyl)-substituted benzamide derivative or salts thereof
US4528393A (en) Derivatives having expectorant activity, the procedure for their preparation and the pharmaceutical compositions which contain them
DD279674A5 (en) PROCESS FOR PREPARING HYDROGENATED 1-BENZOOXACYCLOALKYL-PYRIDINCARBONE ACID COMPOUNDS
EP0326106B1 (en) Alkylene diamines
JPS6147838B2 (en)
JPS6015616B2 (en) Method for producing N-2-(pyrrolidinylmethyl)-substituted benzamide derivative or salts thereof
AT200578B (en) Process for the preparation of new N-aminoalkyl derivatives of azepines
US3139441A (en) Alpha (3, 4 dihidroxy phenyl)-beta-(nu-3, 14'-methylenedioxy-phenyl)-alkylamino ethanols
CA2266510A1 (en) N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics
JPS6055503B2 (en) Novel substituted benzamide, its production method, and antiemetics containing it as an active ingredient
NO124430B (en)
JPS63227570A (en) Isoquinoline derivative
FI74456B (en) FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT AKTIVA CYSTINDERIVAT.
US2704284A (en) Therapeutic compounds
US2648666A (en) Quaternary ammonium salts derived
JPH02145572A (en) N-substituted amide
US2674615A (en) 1-arylcycloalkane 1-thiocar-boxylates
FI73197C (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT NYTT, VAENSTERVRIDANDE, TERAPEUTISKT VERKANDE BASISKT DERIVAT AV 9,10-ETANOANTRACEN.
IE42051B1 (en) Esters derived from indole-3-carboxylic acid
EP0650966A1 (en) Process for the preparation of a benzo(a)quinolizinone derivative
JPH06184152A (en) New compound, its production and brain function improver using the same as main ingredient
JPS6016931B2 (en) Method for producing substituted benzoic acid amide
JPS6036423B2 (en) New hydrazine production method